Renaissance Capital logo

Zentalis Pharmaceuticals Priced, Nasdaq: ZNTL

Phase 1/2 biotech developing novel small molecule therapies for various cancers.

Industry: Health Care

First Day Return: +28.9%

Industry: Health Care

We are a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers. We use our highly efficient drug discovery engine, which we refer to as our Integrated Discovery Engine, to identify targets and develop small molecule new chemical entities, or NCEs, with properties that we believe could result in potentially differentiated product profiles. Our discovery engine combines our extensive experience and capabilities across cancer biology and medicinal chemistry. We believe our product candidates are differentiated from current programs targeting similar pathways and, if approved, have the potential to significantly impact clinical outcomes of patients with cancer.
more less
IPO Data
IPO File Date 03/06/2020
Offer Price $18.00
Price Range $16.00 - $18.00
Offer Shares (mm) 9.2
Deal Size ($mm) $165
Lock-Up Date IPO Pro Only
Street Research IPO Pro Only
IPO Data
IPO Date 04/02/2020
Offer Price IPO Intelligence Only
Price Range IPO Intelligence Only
Offer Shares (mm) IPO Intelligence Only
Deal Size ($mm) $165
Lock-Up Date IPO Intelligence Only
Street Research IPO Intelligence Only
Underwriters
IPO Intelligence Only
Company Data
Headquarters New York, NY, United States
Founded 2014
Employees at IPO 62
Website www.zentalis.com

Zentalis Pharmaceuticals (ZNTL) Performance